Search results
Showing 3151 to 3200 of 4138 results for patient
Middle meningeal artery embolisation for chronic subdural haematomas
In development Reference number: GID-IPG10440 Expected publication date: TBC
We are listening to your views on this Interventional procedures guidance. Comments close 19 December 2025.
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]
Awaiting development Reference number: GID-TA11530 Expected publication date: TBC
Middle meningeal artery embolisation for chronic subdural haematomas: draft scope consultation
We are listening to your views on this Interventional procedures guidance. Comments close 7 January 2026.
Evidence-based recommendations on photodynamic therapy for bile duct cancer. This involves injecting a photosensitising agent into the body that is then activated by a small laser to destroy cancer cells and shrink the blockage.
View recommendations for IPG134Show all sections
Sections for IPG134
Bipolar, schizophrenia and other psychoses: register (lithium therapy) (IND256)
This indicator covers the contractor establishing and maintaining a register of patients with schizophrenia, bipolar affective disorder and other psychoses, and other patients on lithium therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM240
This indicator covers establishing and maintaining a register of all patients aged 17 or over with diabetes mellitus, which specifies the type of diabetes where a diagnosis has been confirmed. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM41
Arimoclomol for treating Niemann-Pick disease Type C [ID1312]
In development Reference number: GID-HST10037 Expected publication date: TBC
Evidence-based recommendations on endovascular closure of patent ductus arteriosus. This involves placing a blocking device into the heart, which stays in place permanently and the body’s tissue grows around it.
View recommendations for IPG97Show all sections
Sections for IPG97
Evidence-based recommendations on endovascular closure of atrial septal defect. This involves inserting a small blocking device into the heart, which is gently inflated to close the hole.
View recommendations for IPG96Show all sections
Sections for IPG96
Artificial trapeziometacarpal joint replacement for end-stage osteoarthritis (IPG111)
Evidence-based recommendations on artificial trapeziometacarpal joint replacement for treating end-stage osteoarthritis. This involves replacing the arthritic joint at the base of the thumb with an artificial joint.
View recommendations for IPG111Show all sections
Sections for IPG111
Coil embolisation of ruptured intracranial aneurysms (IPG106)
Evidence-based recommendations on coil embolisation of ruptured intracranial aneurysms. This involves passing a thin tube through the body to place coils inside the aneurysm.
View recommendations for IPG106Show all sections
Sections for IPG106
Macular translocation with 360° retinotomy for wet age-related macular degeneration (IPG340)
Evidence-based recommendations on macular translocation with 360° retinotomy for wet age-related macular degeneration. This involves cutting and moving the macula on to a nearby healthier area of the choroid layer.
View recommendations for IPG340Show all sections
This indicator covers the proportion of people who have had an acute stroke who receive thrombolysis for stroke. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG50
Extracorporeal membrane oxygenation (ECMO) in postneonatal children (IPG38)
Evidence-based recommendations on extracorporeal membrane oxygenation in postneonatal children. This involves connecting the child's internal circulation to an external blood pump and artificial lung.
View recommendations for IPG38Show all sections
Sections for IPG38
This indicator covers the percentage of patients (excluding those on the CKD register) prescribed long-term (chronic) oral non-steroidal anti-inflammatory drugs (NSAIDs) who have had an eGFR measurement in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM214.
This indicator covers the proportion of patients with ST-segment elevation myocardial infarction (STEMI) who had coronary reperfusion therapy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG91
This indicator covers producing a register of all patients aged 16 years and over with rheumatoid arthritis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM55
Image-guided vacuum-assisted excision biopsy of benign breast lesions (IPG156)
Evidence-based recommendations on image-guided vacuum-assisted excision biopsy for benign breast lesions. This involves inserting a needle with a suction device through a small opening in the breast to remove non-cancerous lumps.
View recommendations for IPG156Show all sections
Sections for IPG156
Evidence-based recommendations on intraoperative flourescence angiography in coronary artery bypass grafting. This involves injecting a small amount of a special dye into the blood vessels near to the heart, using a small laser to activitate it and tracking the dye with a video camera.
View recommendations for IPG98Show all sections
Sections for IPG98
Evidence-based recommendations on bulevirtide (Hepcludex) for chronic hepatitis D in adults.
Guselkumab for treating moderately to severely active ulcerative colitis (TA1094)
Evidence-based recommendations on guselkumab (Tremfya) for treating moderately to severely active ulcerative colitis in adults.
Guselkumab for previously treated moderately to severely active Crohn's disease (TA1095)
Evidence-based recommendations on guselkumab (Tremfya) for previously treated moderately to severely active Crohn's disease.
Evidence-based recommendations on auditory brain stem implants for deafness caused by damage to the vestibulocochlear nerve due to tumours or surgery. This involves placing an implant in the part of the brain that processes sound signals, bypassing the nerve, to pick up electrical signals from a sound processor worn outside the ear.
View recommendations for IPG108Show all sections
Sections for IPG108
This indicator covers the percentage of urgent suspected colorectal cancer referrals accompanied by a faecal immunochemical test (FIT) result, with the result recorded in the 21 days leading up to the referral. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM251.
This indicator covers the percentage of patients with asthma on the register aged 19 or under, in whom there is a record of smoking status (active or passive) in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM168
Atrial fibrillation: current treatment with anticoagulation (IND128)
This indicator covers the percentage of patients who are currently treated with anticoagulation drug therapy in those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM82
This indicator covers the percentage of patients with rheumatoid arthritis who have had a face-to-face annual review in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM58
Weight management: referral to weight management programmes for obesity (IND220)
This indicator covers the percentage of patients with a BMI of 27.5 kg/m2 or more (or 30 kg/m2 or more if ethnicity is recorded as White) in the preceding 12 months who have been offered referral to a weight management programme within 90 days of the BMI being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM202
This indicator covers mortality rates directly associated with VTE. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG80
Lipids disorders: FH assessment (30 years and over) (IND204)
This indicator covers the percentage of people aged 30 years and older with a total cholesterol concentration greater than 9.0 mmol/l that are assessed against the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM183
Evidence-based recommendations on total wrist replacement. This involves creating an artificial wrist joint consisting of metal implants attached to the end of the arm and to the hand, separated by a spacer to allow movement.
View recommendations for IPG271Show all sections
Sections for IPG271
We are listening to your views on this Technology appraisal guidance. Comments close 8 January 2026.
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983]
Awaiting development Reference number: GID-TA10879 Expected publication date: TBC
This indicator covers the percentage of patients with a new diagnosis of dementia recorded in the preceding 1 April to 31 March with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded between 6 months before or after entering on to the register. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM09
Evidence-based recommendations on collagen injection for vocal cord augmentation. This involves injecting collagen into the affected vocal cord(s).
View recommendations for IPG130Show all sections
Sections for IPG130
Intraoperative nerve monitoring during thyroid surgery (IPG255)
Evidence-based recommendations on intraoperative nerve monitoring during thyroid surgery. This involves placing electrodes near the vocal cords to alert the surgeon when a surgical instrument comes close to either of the laryngeal nerves.
View recommendations for IPG255Show all sections
Sections for IPG255
Percutaneous radiofrequency ablation for atrial fibrillation (IPG168)
Evidence-based recommendations on percutaneous radiofrequency ablation for atrial fibrillation. This involves inserting a catheter into the heart that produces heat to damage the nerves in the area with the abnormal elecritcal impulses.
View recommendations for IPG168Show all sections
Sections for IPG168
Evidence-based recommendations on photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions). This involves applying (or sometimes injecting) a photosensitising agent and using light to activate it, destroying the tumour cells.
View recommendations for IPG155Show all sections
Sections for IPG155
Kidney conditions: CKD and blood pressure when ACR less than 70 (IND235)
This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of less than 70 mg/mmol, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM217
Hypertension: brief intervention to increase physical activity (IND96)
This indicator covers the percentage of patients with hypertension aged 16 or over and who have not attained the age of 75 who score ‘less than active’ on GPPAQ in the preceding 15 months, who also have a record of a brief intervention in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM37
This indicator covers the percentage of patients with hypertension aged 16 to 74 years in whom there is an annual assessment of physical activity, using GPPAQ, in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM36
Alcohol use: brief intervention for people with SMI (IND200)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses with a FAST score of 3 or more or AUDIT-C score of 5 or more in the preceding 12 months who have received a brief intervention to help them reduce their alcohol related risk within 3 months of the score being recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM179
This indicator covers the contractor establishing and maintaining a register of patients with asthma aged 5 or over. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM165
This indicator covers the proportion of people in the National Hip Fracture Database who have received all 8 care processes. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG23
Rheumatoid arthritis: cardiovascular risk assessment (IND108)
This indicator covers the percentage of patients with rheumatoid arthritis (RA) aged 30 to 84 years who have had a cardiovascular risk assessment using a cardiovascular disease (CVD) risk assessment tool adjusted for RA in the preceding 15 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM56
Laparoscopic insertion of peritoneal dialysis catheter (IPG208)
Evidence-based recommendations on laparoscopic insertion of peritoneal dialysis catheter. This involves inserting a tube through small cuts (keyhole surgery) in the abdomen to remove waste product from the blood.
View recommendations for IPG208Show all sections
Sections for IPG208
Automated percutaneous mechanical lumbar discectomy (IPG141)
Evidence-based recommendations on automated percutaneous mechanical lumbar discectomy. This involves using an automated device to cut and remove the part of the disc that’s pressing on the nerve.
View recommendations for IPG141Show all sections
Sections for IPG141
Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]
Discontinued Reference number: GID-TA10105
Transpupillary thermotherapy for age-related macular degeneration (IPG58)
Evidence-based recommendations on transpupillary thermotherapy for age-related macular degeneration. This involves using a laser to heat and seal up the blood vessels that are causing the problems.
View recommendations for IPG58Show all sections
Sections for IPG58